NO922155L - Peptider og antistoffer som inhiberer integrinligandbinding - Google Patents

Peptider og antistoffer som inhiberer integrinligandbinding

Info

Publication number
NO922155L
NO922155L NO92922155A NO922155A NO922155L NO 922155 L NO922155 L NO 922155L NO 92922155 A NO92922155 A NO 92922155A NO 922155 A NO922155 A NO 922155A NO 922155 L NO922155 L NO 922155L
Authority
NO
Norway
Prior art keywords
integrinigandand
peptides
binding
antibodies inhibiting
antibodies
Prior art date
Application number
NO92922155A
Other languages
English (en)
Other versions
NO922155D0 (no
Inventor
Edward F Plow
Souza Stanley E D
Mark H Ginsberg
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Publication of NO922155D0 publication Critical patent/NO922155D0/no
Publication of NO922155L publication Critical patent/NO922155L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO92922155A 1989-12-01 1992-05-29 Peptider og antistoffer som inhiberer integrinligandbinding NO922155L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/444,777 US5196511A (en) 1989-12-01 1989-12-01 Peptides and antibodies that inhibit integrin-ligand binding
PCT/US1990/006954 WO1991007977A1 (en) 1989-12-01 1990-11-29 Peptides and antibodies that inhibit integrin-ligand binding

Publications (2)

Publication Number Publication Date
NO922155D0 NO922155D0 (no) 1992-05-29
NO922155L true NO922155L (no) 1992-07-31

Family

ID=23766316

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92922155A NO922155L (no) 1989-12-01 1992-05-29 Peptider og antistoffer som inhiberer integrinligandbinding

Country Status (8)

Country Link
US (1) US5196511A (no)
EP (1) EP0502124A4 (no)
JP (1) JP3315403B2 (no)
AU (1) AU645770B2 (no)
CA (1) CA2069902A1 (no)
FI (1) FI922454A0 (no)
NO (1) NO922155L (no)
WO (1) WO1991007977A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773574A (en) * 1990-12-03 1998-06-30 The Scripps Research Institute Polypeptides for promoting cell attachment
EP0583352B1 (en) 1991-04-30 1999-09-08 The Scripps Research Institute hGPIIb FRAGMENTS AND THEIR USE IN $i(IN VITRO) METHODS FOR DETERMINING $i(IN VIVO) THROMBOTIC EVENTS
SK57693A3 (en) * 1992-06-18 1994-07-06 Merck Patent Gmbh Linear peptides and pharmaceutical agents on their base
ATE210452T1 (de) * 1992-10-02 2001-12-15 Alberta Res Council Entzündungshemmende tolerogene und immunoinhibitorische eigenschaften von karbohydrate bindende peptide
US5453272A (en) * 1992-10-02 1995-09-26 Alberta Research Council Lectin derived carbohydrate binding-peptide
DE4310632A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Lineare Adhäsionsinhibitoren
US5594120A (en) 1994-02-18 1997-01-14 Brigham And Women's Hospital, Inc. Integrin alpha subunit
US5523209A (en) * 1994-03-14 1996-06-04 The Scripps Research Institute Methods for identifying inhibitors of integrin activation
WO1995028170A1 (en) * 1994-04-19 1995-10-26 The University Of Kansas Icam-1/lfa-1 short-chain peptides and method of using same
US5610281A (en) 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
US5817750A (en) * 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
EP0973797A4 (en) * 1996-04-26 2002-01-16 Univ Kansas PEPTIDE COMPOSITIONS FOR GENERATING IMMUNOL TOLERANCE AND METHOD FOR THEIR USE
WO1998032771A1 (en) * 1997-01-29 1998-07-30 Toray Industries, Inc. Chimeric proteins, heterodimer complexes thereof and substitute for platelet
US6046316A (en) * 1997-12-09 2000-04-04 Wayne State University Nucleic acid encoding truncated integrins
US7618630B2 (en) * 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
CA2439852A1 (en) * 2001-03-02 2002-09-12 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
WO2003075957A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
CA2478317A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
WO2003086458A1 (en) 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
WO2004066956A2 (en) * 2003-01-30 2004-08-12 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
ES2388068T3 (es) * 2004-12-23 2012-10-08 Molmed Spa Producto de conjugación
AU2006315037C1 (en) * 2005-11-18 2013-05-02 Ichnos Sciences SA Anti-alpha2 integrin antibodies and their uses
EP2043603A4 (en) 2006-07-11 2010-10-27 Arubor Corp PREVENTION AND THERAPY OF RHINOSINUSITIS WITH PROINFLAMMATORY CYTOKINHERMERS
US20080039362A1 (en) * 2006-08-09 2008-02-14 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
HUE048024T2 (hu) 2006-08-10 2020-05-28 Roy C Levitt Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114842A (en) * 1987-07-08 1992-05-19 The Scripps Research Institute Peptides and antibodies that inhibit platelet adhesion

Also Published As

Publication number Publication date
NO922155D0 (no) 1992-05-29
FI922454A7 (fi) 1992-05-27
JPH05502228A (ja) 1993-04-22
FI922454L (fi) 1992-05-27
AU645770B2 (en) 1994-01-27
JP3315403B2 (ja) 2002-08-19
US5196511A (en) 1993-03-23
EP0502124A4 (en) 1993-04-28
EP0502124A1 (en) 1992-09-09
AU6911391A (en) 1991-06-26
FI922454A0 (fi) 1992-05-27
CA2069902A1 (en) 1991-06-02
WO1991007977A1 (en) 1991-06-13

Similar Documents

Publication Publication Date Title
NO922155L (no) Peptider og antistoffer som inhiberer integrinligandbinding
FI895346A7 (fi) Sitoutuvia proteiineja
NO921863L (no) Antistoffer og anvendelse derav
DE69410636D1 (de) Bindungsbestimmung
NO962346D0 (no) Humaniserte antistoffer og anvendelser derav
DK540289A (da) Protein
DK111489D0 (da) Peptider
DK197989A (da) Peptidanaloger
FI922220A7 (fi) Spesifiset sitoutumisaineet
DK190889A (da) Antigen
DK221389D0 (da) Fibronectin-bindende protein og fremgangsmaade til fremstilling deraf
DK94091D0 (da) Hdl-bindende proteiner
KR900700503A (ko) 펩티드
DE68914935D1 (de) Bindungsapparat.
FI905453A7 (fi) Prokalsitoniinipeptidejä
DE69223434D1 (de) Calmodulin bindendes Protein
NO901052L (no) 1h-pyrazol-1-acetamider og fremstilling derav.
EP1030859A4 (en) RAS FIXING PROTEIN (PRE1)
NO904846D0 (no) Amfifile peptider og anvendelse derav.
NO911939D0 (no) Hdl-bindende proteiner.
KR950014704U (ko) 구조물 결속용 연결부재
DK207488A (da) Anti-r-bindende antistof
DK381789D0 (da) Peptider
DK73789D0 (da) Heparin-bindende protein
DK145388D0 (da) Heparin-bindende protein